[Tiagabine: a GABA-ergic anti-epileptic drug].
BACKGROUND
Tiagabina (TGB) is a new anti-epileptic drug which inhibits the uptake of GABA by the neurons and glia and prolongs the time GABA remains at the synapse.


METHODS
Experimental studies suggested the efficacy of TGB in generalized tonic-clonic crises, in focal crises and in myoclonic crises. This has been confirmed in the clinical trials carried out in patients and after free use of the drug after being put on sale.


CONCLUSIONS
With few pharmacokinetic interactions, TOB is well tolerated by patients of all ages. This makes it a drug wide good prospects in the ever increasing therapeutic arsenal against
Herranz
J L
JL
Servicio de Neuropediatría, Hospital Universitario Marqués de Valdecilla, Santander, España.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D004361:Drug Tolerance; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009557:Nipecotic Acids / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D018079:Receptors, GABA / Q000187:drug effects*; D013569:Synapses / Q000187:drug effects; D000078308:Tiagabine; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D000927:Anticonvulsants; D009557:Nipecotic Acids; D018079:Receptors, GABA; D005680:gamma-Aminobutyric Acid; D000078308:Tiagabine
Tiagabina: un antiepiléptico GABAérgico.